ORAMED PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ORAMED PHARMACEUTICALS INC. - More news...
ORAMED PHARMACEUTICALS INC. - More news...
- Oramed Letter to Shareholders
- Thinking about buying stock in MicroAlgo, Oramed Pharmaceuticals, Limbach Holdings, Niu Technologies, or Applied Molecular Transport?
- Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
- Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
- Oramed to Present at the 83rd American Diabetes Association Conference
- Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
- Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
- Thinking about buying stock in Zillow, Li Auto, Endeavour Silver, Protalix Biotherapeutics, or Oramed Pharmaceuticals?
- Oramed Appoints Ben Shapiro to its Board of Directors
- Oramed Pharmaceuticals Issues Shareholder Update
- Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
- Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
- Oramed Letter to Shareholders
- Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
- Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
- Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
- Oramed Reports Third Quarter 2022 Financial Results
- Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
- Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
- Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
- Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
- Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
- Oramed Letter to Shareholders
- Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
- Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
- Oramed to Present at H.C. Wainwright Global Investment Conference
- Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
- Oramed Granted NASH Patent in Europe
- Oramed Appoints Yadin Rozov to its Board of Directors
